NEW YORK – Envisagenics announced Tuesday it has entered into a research program agreement with Johnson & Johnson's Lung Cancer Initiative (LCI.)
Under the terms of the agreement, Envisagenics will build predictive models for lung cancer progression and risk and use its SpliceCore software platform to analyze LCI's data.
Financial and other details were not disclosed.